Other Consolidated Financial Statement Detail (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Other Income (Expense), Net
Interest income	$ 1,500,000	$ 5,900,000	$ 6,700,000	$ 22,600,000
Interest expense	(6,600,000)	(8,700,000)	(25,500,000)	(23,100,000)
Impairment of investments	0	(3,500,000)	(1,700,000)	(4,800,000)
Gain (loss) on sales of investments, net	3,900,000	1,300,000	14,000,000	15,600,000
Foreign exchange gains (losses), net	(3,100,000)	100,000	(11,000,000)	200,000
Other, net	(300,000)	400,000	(12,000,000)	3,100,000
Total other income (expense), net	(4,640,000)	(4,548,000)	(29,525,000)	13,546,000
Accrued Expenses and Other
Employee-related Liabilities	261,500,000		261,500,000		248,500,000
Revenue-related rebates	247,400,000		247,400,000		191,000,000
Deferred revenue	240,700,000		240,700,000		148,000,000
Royalties and licensing fees	117,300,000		117,300,000		45,200,000
Clinical development expenses	57,100,000		57,100,000		51,600,000
Production expenses accrual	43,600,000		43,600,000		45,600,000
Current portion of contingent consideration obligations	29,100,000		29,100,000		22,400,000
Construction in progress accrual	21,900,000		21,900,000		12,300,000
Other	185,800,000		185,800,000		215,300,000
Total accrued expenses and other	$ 1,204,437,000		$ 1,204,437,000		$ 979,945,000